Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

OBJECTIVES: To assess long-term efficacy, safety and tolerability of secukinumab up to 104 weeks in patients with active PsA. METHODS: Patients with PsA (n = 397) were randomized to s.c. secukinumab 300, 150 or 75 mg or placebo at baseline, weeks 1, 2, 3 and 4 and every 4 weeks thereafter. Placebo-t...

Descripción completa

Detalles Bibliográficos
Autores principales: McInnes, Iain B, Mease, Philip J, Ritchlin, Christopher T, Rahman, Proton, Gottlieb, Alice B, Kirkham, Bruce, Kajekar, Radhika, Delicha, Eumorphia-Maria, Pricop, Luminita, Mpofu, Shephard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850284/
https://www.ncbi.nlm.nih.gov/pubmed/28968735
http://dx.doi.org/10.1093/rheumatology/kex301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850284/
https://www.ncbi.nlm.nih.gov/pubmed/28968735
http://dx.doi.org/10.1093/rheumatology/kex301

Ejemplares similares